Thompson Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.3M Buy
469,287
+5,116
+1% +$134K 1.3% 22
2026
Q1
$13M Buy
464,171
+716
+0.2% +$19.1K 1.69% 8
2025
Q4
$11.5M Buy
463,455
+35,325
+8% +$891K 1.45% 16
2025
Q3
$10.9M Buy
428,130
+12,134
+3% +$299K 1.46% 17
2025
Q2
$10.1M Buy
415,996
+5,151
+1% +$120K 1.42% 16
2025
Q1
$10.4M Buy
410,845
+7,381
+2% +$193K 1.56% 13
2024
Q4
$10.7M Buy
403,464
+22,179
+6% +$602K 1.54% 13
2024
Q3
$11M Buy
381,285
+5,357
+1% +$156K 1.58% 13
2024
Q2
$10.5M Buy
375,928
+7,703
+2% +$212K 1.62% 11
2024
Q1
$10.2M Buy
368,225
+12,651
+4% +$351K 1.55% 14
2023
Q4
$10.2M Buy
355,574
+206,174
+138% +$6.23M 1.65% 11
2023
Q3
$4.96M Buy
149,400
+5,217
+4% +$184K 0.88% 44
2023
Q2
$5.29M Buy
144,183
+11,577
+9% +$451K 0.86% 43
2023
Q1
$5.41M Buy
132,606
+64,440
+95% +$2.78M 0.92% 42
2022
Q4
$3.49M Hold
68,166
0.64% 60
2022
Q3
$2.98M Sell
68,166
-3,468
-5% -$169K 0.58% 66
2022
Q2
$3.76M Sell
71,634
-1,100
-2% -$56.1K 0.65% 59
2022
Q1
$3.77M Sell
72,734
-430
-0.6% -$22.3K 0.55% 64
2021
Q4
$4.32M Sell
73,164
-28,525
-28% -$1.41M 0.61% 63
2021
Q3
$4.37M Sell
101,689
-345
-0.3% -$15.3K 0.65% 57
2021
Q2
$4M Buy
102,034
+8,550
+9% +$332K 0.58% 64
2021
Q1
$3.39M Buy
93,484
+89
+0.1% +$3.16K 0.51% 74
2020
Q4
$3.44M Buy
93,395
+19,805
+27% +$726K 0.58% 67
2020
Q3
$2.56M Buy
73,590
+354
+0.5% +$12.4K 0.48% 73
2020
Q2
$2.27M Sell
73,236
-2,635
-3% -$89.5K 0.44% 76
2020
Q1
$2.35M Hold
75,871
0.52% 65
2019
Q4
$2.82M Buy
75,871
+2,375
+3% +$84.6K 0.46% 76
2019
Q3
$2.5M Buy
73,496
+782
+1% +$28.4K 0.49% 76
2019
Q2
$2.99M Buy
72,714
+8,432
+13% +$335K 0.58% 71
2019
Q1
$2.59M Buy
64,282
+181
+0.3% +$7.25K 0.5% 75
2018
Q4
$2.65M Sell
64,101
-17,165
-21% -$713K 0.62% 65
2018
Q3
$3.4M Sell
81,266
-5,254
-6% -$202K 0.61% 73
2018
Q2
$2.98M Sell
86,520
-1,865
-2% -$63.7K 0.54% 75
2018
Q1
$2.98M Buy
88,385
+36,732
+71% +$1.26M 0.55% 76
2017
Q4
$1.77M Sell
51,653
-52
-0.1% -$1.77K 0.31% 82
2017
Q3
$1.75M Hold
51,705
0.33% 83
2017
Q2
$1.65M Sell
51,705
-1,054
-2% -$33.2K 0.31% 85
2017
Q1
$1.71M Buy
52,759
+764
+1% +$24.1K 0.33% 84
2016
Q4
$1.6M Buy
51,995
+42,411
+443% +$1.29M 0.31% 85
2016
Q3
$308K Hold
9,584
0.06% 147
2016
Q2
$320K Buy
9,584
+153
+2% +$4.88K 0.07% 143
2016
Q1
$265K Sell
9,431
-68
-0.7% -$1.94K 0.06% 150
2015
Q4
$291K Buy
9,499
+742
+8% +$23.3K 0.06% 146
2015
Q3
$261K Sell
8,757
-949
-10% -$30.4K 0.06% 150
2015
Q2
$309K Buy
9,706
+621
+7% +$20.2K 0.06% 139
2015
Q1
$300K Sell
9,085
-527
-5% -$16.8K 0.06% 143
2014
Q4
$284K Sell
9,612
-125
-1% -$3.58K 0.05% 146
2014
Q3
$277K Sell
9,737
-1,483
-13% -$41.6K 0.05% 150
2014
Q2
$316K Hold
11,220
0.06% 137
2014
Q1
$342K Buy
11,220
+200
+2% +$5.96K 0.07% 136
2013
Q4
$320K Buy
11,020
+2,521
+30% +$73.4K 0.06% 139
2013
Q3
$232K Sell
8,499
-527
-6% -$14.3K 0.05% 154
2013
Q2
$240K Buy
+9,026
New +$249K 0.06% 143

Other funds holding PFE

Thompson Investment Management's PFE Position: Q2 2026 in Review

Thompson Investment Management increased its Pfizer (PFE) stake by 1.1% in Q2 2026, buying an estimated $134K and bringing the position to 469,287 shares worth $11.3M. The position accounts for 1.3% of the portfolio, ranked #22.

Thompson Investment Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $13M in Q1 2026. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Thompson Investment Management held 469,287 shares of Pfizer worth $11.3M as of Q2 2026.
  • Thompson Investment Management bought 5,116 Pfizer shares in Q2 2026, an estimated $134K.
  • Pfizer made up 1.3% of Thompson Investment Management's portfolio in Q2 2026, its #22 holding.
  • Thompson Investment Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Thompson Investment Management's Pfizer position peaked at $13M in Q1 2026.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Thompson Investment Management's 13F filing for Q2 2026, filed 13 Jul 2026.